Jefferies Group reiterated their buy rating on shares of Alcobra Ltd. (NASDAQ:ADHD) in a research note released on Monday. Jefferies Group currently has a $6.00 price objective on the stock, down from their previous price objective of $9.00.
Other analysts have also recently issued research reports about the company. Goldman Sachs Group Inc. reaffirmed a buy rating on shares of Alcobra in a research report on Thursday, September 1st. Cantor Fitzgerald reissued a buy rating and issued a $16.00 price objective on shares of Alcobra in a report on Wednesday, August 31st. Roth Capital reissued a buy rating and issued a $12.00 price objective on shares of Alcobra in a report on Tuesday, June 21st. Canaccord Genuity started coverage on Alcobra in a report on Tuesday, June 7th. They issued a buy rating for the company. Finally, Barclays PLC started coverage on Alcobra in a report on Monday, August 1st. They issued an equal weight rating and a $8.00 price objective for the company. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company. The company has a consensus rating of Hold and an average target price of $6.47.
Alcobra (NASDAQ:ADHD) opened at 2.60 on Monday. The stock’s market cap is $71.66 million. Alcobra has a 12-month low of $1.95 and a 12-month high of $8.78. The firm’s 50-day moving average price is $4.41 and its 200 day moving average price is $4.46.
Alcobra (NASDAQ:ADHD) last issued its quarterly earnings results on Tuesday, August 30th. The company reported ($0.21) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.01. Analysts anticipate that Alcobra will post ($0.94) EPS for the current year.
A number of institutional investors have recently added to or reduced their stakes in the company. Franklin Resources Inc. boosted its position in Alcobra by 28.2% in the first quarter. Franklin Resources Inc. now owns 3,652,931 shares of the company’s stock worth $13,845,000 after buying an additional 804,350 shares during the last quarter. VHCP Management II LLC boosted its position in Alcobra by 28.7% in the second quarter. VHCP Management II LLC now owns 1,454,402 shares of the company’s stock worth $6,530,000 after buying an additional 323,902 shares during the last quarter. VHCP Management LLC boosted its position in Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock worth $2,799,000 after buying an additional 138,813 shares during the last quarter. Jefferies Group LLC acquired a new position in Alcobra during the second quarter worth $533,000. Finally, BlackRock Fund Advisors boosted its position in Alcobra by 11.4% in the first quarter. BlackRock Fund Advisors now owns 354,614 shares of the company’s stock worth $1,344,000 after buying an additional 36,218 shares during the last quarter. 73.69% of the stock is owned by institutional investors.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.